You are here

BeiGene

BeiGene Presents Encouraging Results in Ph I Trial of Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors

Flag link:

Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation

Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation

South China Morning Post

Flag link:

BeiGene Proposes $800+ Million Offering

BeiGene Proposes $800+ Million Offering

CP Wire

Flag link:

BeiGene Proposes $800+ Million Offering

Flag link:

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

CP Wire

monoclonal antibodies

Flag link:

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

checkpoint inhibitors

Flag link:

Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test

Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test

Endpoints

Hodgkin's lymphoma

Flag link:

BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Patients with Ovarian Cancer

BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Patients with Ovarian Cancer

CP Wire

clinical trials

Flag link:

BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Patients with Ovarian Cancer

Flag link:

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

Motley Fool

Flag link:

Boehringer, BeiGene enter manufacturing pact for PD-1 drug

Boehringer, BeiGene enter manufacturing pact for PD-1 drug

Biopharma Dive

Boehringer Ingelheim

drug manufacturing

Flag link:

Unstoppable growth of Chinese biotechs attracts over $10bn funding

Unstoppable growth of Chinese biotechs attracts over $10bn funding

GoinPharma

Flag link:

Prescribed Reading: I/O is the only game in town

Prescribed Reading: I/O is the only game in town

BioPharma Dive

immuno-oncology

Endo International

Vertex Pharmaceuticals

Bristol-Myers Squibb

Flag link:

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

Endpoints

Flag link:

China's BeiGene banks $97M to get its cancer drugs into the clinic

China's BeiGene banks $97M to get its cancer drugs into the clinic

Fierce Biotech

Flag link:

China Biotech In Review: Eli Lilly Joins The Big Pharmas Accused Of Bribing In China

China Biotech In Review: Eli Lilly Joins The Big Pharmas Accused Of Bribing In China

Seeking Alpha

Zhejiang Beta Pharma

Flag link:

China Biotech In Review: Valeant Pharma Gains Sales Foothold In China With Bausch & Lomb Buy

China Biotech In Review: Valeant Pharma Gains Sales Foothold In China With Bausch & Lomb Buy

Seeking Alpha

Valeant Pharmaceuticals

Tongjitang Chinese Medicines

Sinovac Biotech

Vigoo Biological

Flag link:

BeiGene And Merck & Co To Discover Cancer Medicines

BeiGene And Merck & Co To Discover Cancer Medicines

Pharmceutical Insight

Flag link:

China’s Cancer Deaths Spur Merck Investment in Beijing Biotech

China’s Cancer Deaths Spur Merck Investment in Beijing Biotech

Bloomberg

Flag link: